阿伐曲泊帕治疗中国儿童持续性及慢性原发性免疫性血小板减少症的有效性与安全性:中国多中心观察性回顾性研究
本研究为多中心回顾性观察研究,纳入34例持续性或慢性ITP患儿,既往治疗无效或复发后接受阿伐曲泊帕至少12周。4周内总体反应率79.4%、完全反应率67.7%,12周总体反应率88.2%、持续反应率44%,出血及合并用药减少,无显著不良事件。
要点
- 阿伐曲泊帕治疗儿童持续性或慢性ITP,4周内总体反应率79.4%,中位起效时间7天。
- 12周时总体反应率88.2%,完全反应率76.5%,持续反应率44%。
- 1-3级出血比例从基线52.95%降至12周2.94%,合并ITP用药从36.47%降至8.82%。
核心结论
- 阿伐曲泊帕作为二线治疗可使持续性或慢性ITP患儿获得快速且持续的反应,出血控制良好并减少合并ITP治疗,无显著不良事件。
研究设计与样本
- 多中心、回顾性、观察性研究,纳入2020年8月至2022年12月间34例(男18例)持续性或慢性ITP患儿,平均年龄6.3岁(范围1.9-15.3),既往治疗中位种类4种(范围1-6),41.2%曾换用其他TPO-RA,接受阿伐曲泊帕至少12周。
主要发现
- 4周内总体反应率79.4%,完全反应率67.7%,中位起效时间7天(范围1-27)。
- 12周时总体反应率88.2%,完全反应率76.5%,持续反应率44%。
- 24周时22/34例(64.7%)获得反应并随访至24周的患者中,12/22例(54.55%)达到持续反应。
- 1-3级出血比例从基线52.95%降至12周2.94%,合并ITP用药从基线36.47%降至12周8.82%,12周内仅9例(26.47%)接受23次挽救治疗。
- 61.8%患者发生59例不良事件,其中29.8%为CTCAE 1级,其余为2级。
关键数值与推荐
- 反应定义为血小板计数≥30×10^9/L、较基线翻倍且无出血;完全反应定义为血小板计数≥100×10^9/L且无出血。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Avatrombopag (AVA) is a novel thrombopoietin receptor agonist (TPO-RA) that has been recently approved as a second-line therapy for immune thrombocytopenia (ITP) in adults; however, its safety and efficacy data in children are lacking. Here, we demonstrated the efficacy and safety of AVA as second-line therapy in children with ITP. A multicentre, retrospective, observational study was conducted in children with persistent or chronic ITP who did not respond to or relapsed from previous treatment and were treated with AVA for at least 12 weeks between August 2020 and December 2022. The outcomes were the responses (defined as achieving a platelet count ≥30 × 109/L, twofold increase in platelet count from baseline and absence of bleeding), including rapid response within 4 weeks, sustained response at weeks 12 and 24, bleeding control and adverse events (AEs). Thirty-four (18 males) patients with a mean age of 6.3 (range: 1.9-15.3) years were enrolled. The median number of previous treatment types was four (range: 1-6), and 41.2% patients switched from other TPO-RAs. Within 4 weeks, overall response (OR) was achieved in 79.4% patients and complete response (CR, defined as a platelet count ≥100 × 109/L and the absence of bleeding) in 67.7% patients with a median response time of 7 (range: 1-27) days. At 12 weeks, OR was achieved in 88.2%, CR in 76.5% and sustained response in 44% of patients. At 24 weeks, 22/34 (64.7%) patients who achieved a response and were followed up for 24 weeks were evaluated; 12/22 (54.55%) achieved a sustained response. During AVA therapy, median platelet counts increased by week 1 and were maintained throughout the treatment period. The proportion of patients with grade 1-3 bleeding decreased from 52.95% at baseline to 2.94% at 12 weeks, while concomitant ITP medications decreased from 36.47% at baseline to 8.82% at 12 weeks, with only 9 (26.47%) patients receiving rescue therapy 23 times within 12 weeks. There were 61.8% patients with 59 AEs: 29.8% with Common Terminology Criteria for Adverse Events grade 1 and the rest with grade 2. These findings show that AVA could achieve a rapid and sustained response in children with persistent or chronic ITP as a second-line treatment, with good clinical bleeding control and reduction of concomitant ITP therapy, without significant AEs.
引用
- Wang Z, Zhang A, Xu Z, et al. Efficacy and safety of avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China. Br J Haematol. 2024. PMID: 38362793. doi:10.1111/bjh.19342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。